Textbook of Catheter-Based Cardiovascular Interventions pp 1689-1696 | Cite as
Patent Foramen Ovale Closure
A patent foramen ovale (PFO) persists in approximately 15–30% of adults, and its frequency decreases with age. In combination with predisposing morphological and hemodynamic conditions, this remnant interatrial communication promotes thromboembolic events—most notably, cerebrovascular events. Feasible treatment strategies include antithrombotic medication (antiplatelet therapy or anticoagulation), surgery, or transcatheter defect closure. Data from three large randomized controlled trials have recently provided evidence that PFO closure is associated with a lower rate of recurrent ischemic stroke than antiplatelet therapy alone in patients with a PFO and recent cryptogenic stroke. Current guidelines promote medical therapy over endovascular or surgical PFO closure as a first-line therapy in patients with cryptogenic stroke and a PFO. This chapter reviews the pathophysiology of presumed paradoxical embolism through a PFO, current guidelines, the history and current status of device technology, and critical aspects to consider when facing a residual shunt after transcatheter PFO closure.
- 13.Cohnheim J. Thrombose und Embolie. In: Vorlesungen űber Allgemeine Pathologie. Berlin: Hirschwald. p. 18771134.Google Scholar
- 24.Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e601S–36S.Google Scholar
- 26.Messé SR, Gronseth G, Kent DM, et al. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter): report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(8):815–21.CrossRefGoogle Scholar
- 27.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm527096.htm (accessed January 28, 2018).
- 29.Mullen M. NobleStitch multi-center trial. CSI Congress 2016, Congenital, Structural & Valvular Interventions; 2016; Frankfurt.Google Scholar